Hi Michele,
I was on the online ASCO website a few days ago and it looks like an interesting intinerary. Click on the abstracts, on the ASCO site, and they will down load for you. I think you will be very interested in hearing the discussion on potential cardiac side effects from Lapatinib, I think Piccart is the speaker for that lecture. Also, Dr. Neil Spector, an oncologist and researcher at GSK, is speaking on Lapatinib again at the ASCO. According to Dr. Spector, there are a few things they are still working out with Lapatinib, which confers with the hold up Dr. Winer is addressing.
I know what you are thinking by wanting Lapatinib, a her1 and her2 antogonist. You were her1+ right? Wasn't that in low to moderate amounts? Perhaps the amounts of positivity does make a difference. For example, from
what I have read it is the high levels her3 that result, at least in some small studies, in disease progression while on Herceptin. But it is the low to moderate levels of her3 that result in stable disease or disease regression. I know we are talking about her3 here but perhaps the same holds true for her1, concerning the significance levels. Certainly, this is something to look into, particularly if you are serious about adjuvant Lapatinib. Keep us posted.
KIT,
Robin
__________________
Robin
2002- dx her2 positive DCIS/bc TX Mast, herceptin chemo
Last edited by RobinP; 05-11-2006 at 07:21 AM..
|